SpringWorks Therapeutics, Inc. (SWTX)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch SWTX
See up to 3 months of SWTX. The 7-day demo opens the 1M and 3M ranges and puts SWTX on your watchlist.
Start 7-day demoLatest SWTX insider trades
About SpringWorks Therapeutics, Inc. (SWTX)
The SEC lists SpringWorks Therapeutics, Inc. under CIK 0001773427, in biological products (no diagnostic substances). It is grouped with Health Care companies on this site.
SWTX Form 4 activity by transaction type, last 90 days
No Form 4 activity for SWTX in the last 90 days.
SWTX insider transactions (Form 4)
9520 Form 4 filings on record, the earliest from Oct 3, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Badreddin Edris - Officer | Derivative | Common Stock | 169,712 | - | - | |
| Badreddin Edris - Officer | Derivative | Performance Share Units | 33,778 | - | - | |
| Badreddin Edris - Officer | Derivative | Stock Option (Right to Buy) | 3,868 | - | - | |
| Badreddin Edris - Officer | Derivative | Stock Option (Right to Buy) | 149,470 | - | - | |
| Badreddin Edris - Officer | Derivative | Stock Option (Right to Buy) | 100,000 | - | - | |
| Badreddin Edris - Officer | Derivative | Stock Option (Right to Buy) | 240,000 | - | - | |
| Badreddin Edris - Officer | Derivative | Stock Option (Right to Buy) | 120,000 | - | - | |
| Badreddin Edris - Officer | Derivative | Stock Option (Right to Buy) | 78,960 | - | - | |
| Tai-An Lin - Officer | Derivative | Common Stock | 33,039 | - | - | |
| Tai-An Lin - Officer | Derivative | Performance Share Units | 8,661 | - | - | |
| Tai-An Lin - Officer | Derivative | Stock Option (Right to Buy) | 75,000 | - | - | |
| Tai-An Lin - Officer | Derivative | Stock Option (Right to Buy) | 15,000 | - | - | |
| Tai-An Lin - Officer | Derivative | Stock Option (Right to Buy) | 20,246 | - | - | |
| Bhavesh Ashar - Officer | Derivative | Common Stock | 62,053 | - | - | |
| Bhavesh Ashar - Officer | Derivative | Performance Share Units | 21,654 | - | - | |
| Bhavesh Ashar - Officer | Derivative | Stock Option (Right to Buy) | 100,000 | - | - | |
| Bhavesh Ashar - Officer | Derivative | Stock Option (Right to Buy) | 70,000 | - | - | |
| Bhavesh Ashar - Officer | Derivative | Stock Option (Right to Buy) | 75,000 | - | - | |
| Bhavesh Ashar - Officer | Derivative | Stock Option (Right to Buy) | 50,615 | - | - | |
| James Cassidy - Officer | Derivative | Common Stock | 81,731 | - | - | |
| James Cassidy - Officer | Derivative | Performance Share Units | 21,654 | - | - | |
| James Cassidy - Officer | Derivative | Stock Option (Right to Buy) | 135,000 | - | - | |
| James Cassidy - Officer | Derivative | Stock Option (Right to Buy) | 80,000 | - | - | |
| James Cassidy - Officer | Derivative | Stock Option (Right to Buy) | 50,615 | - | - | |
| Daniel Pichl - Officer | Derivative | Common Stock | 50,762 | - | - | |
| Daniel Pichl - Officer | Derivative | Performance Share Units | 16,023 | - | - | |
| Daniel Pichl - Officer | Derivative | Stock Option (Right to Buy) | 72,680 | - | - | |
| Daniel Pichl - Officer | Derivative | Stock Option (Right to Buy) | 64,000 | - | - | |
| Daniel Pichl - Officer | Derivative | Stock Option (Right to Buy) | 65,000 | - | - | |
| Daniel Pichl - Officer | Derivative | Stock Option (Right to Buy) | 37,455 | - | - | |
| Michael Nofi - Officer | Derivative | Common Stock | 30,623 | - | - | |
| Michael Nofi - Officer | Derivative | Performance Share Units | 8,661 | - | - | |
| Michael Nofi - Officer | Derivative | Stock Option (Right to Buy) | 78,300 | - | - | |
| Michael Nofi - Officer | Derivative | Stock Option (Right to Buy) | 65,000 | - | - | |
| Michael Nofi - Officer | Derivative | Stock Option (Right to Buy) | 40,000 | - | - | |
| Michael Nofi - Officer | Derivative | Stock Option (Right to Buy) | 20,246 | - | - | |
| Julie Hambleton - Director | Derivative | Common Stock | 14,155 | - | - | |
| Julie Hambleton - Director | Derivative | Stock Option (Right to Buy) | 14,668 | - | - | |
| Julie Hambleton - Director | Derivative | Stock Option (Right to Buy) | 15,318 | - | - | |
| Julie Hambleton - Director | Derivative | Stock Option (Right to Buy) | 12,216 | - | - | |
| Saqib Islam - Officer | Derivative | Common Stock | 954,869 | - | - | |
| Saqib Islam - Officer | Derivative | Performance Share Units | 579,749 | - | - | |
| Saqib Islam - Officer | Derivative | Stock Option (Right to Buy) | 22,760 | - | - | |
| Saqib Islam - Officer | Derivative | Stock Option (Right to Buy) | 769,804 | - | - | |
| Saqib Islam - Officer | Derivative | Stock Option (Right to Buy) | 176,411 | - | - | |
| Saqib Islam - Officer | Derivative | Stock Option (Right to Buy) | 325,000 | - | - | |
| Saqib Islam - Officer | Derivative | Stock Option (Right to Buy) | 260,000 | - | - | |
| Saqib Islam - Officer | Derivative | Stock Option (Right to Buy) | 250,000 | - | - | |
| Saqib Islam - Officer | Derivative | Stock Option (Right to Buy) | 109,329 | - | - | |
 Carlos Alban - Director | Derivative | Common Stock | 28,861 | - | - | |
| Carlos Alban - Director | Derivative | Stock Option (Right to Buy) | 30,160 | - | - | |
| Carlos Alban - Director | Derivative | Stock Option (Right to Buy) | 13,774 | - | - | |
| Carlos Alban - Director | Derivative | Stock Option (Right to Buy) | 12,216 | - | - | |
| Freda C. Lewis-Hall - Director | Derivative | Common Stock | 24,727 | - | - | |
| Freda C. Lewis-Hall - Director | Derivative | Stock Option (Right to Buy) | 29,983 | - | - | |
| Freda C. Lewis-Hall - Director | Derivative | Stock Option (Right to Buy) | 7,464 | - | - | |
| Freda C. Lewis-Hall - Director | Derivative | Stock Option (Right to Buy) | 15,318 | - | - | |
| Freda C. Lewis-Hall - Director | Derivative | Stock Option (Right to Buy) | 13,774 | - | - | |
| Freda C. Lewis-Hall - Director | Derivative | Stock Option (Right to Buy) | 12,216 | - | - | |
| Martin Mackay - Director | Derivative | Common Stock | 20,023 | - | - | |
| Martin Mackay - Director | Derivative | Stock Option (Right to Buy) | 29,445 | - | - | |
| Herschel S. Weinstein - Officer | Derivative | Common Stock | 55,239 | - | - | |
| Herschel S. Weinstein - Officer | Derivative | Performance Share Units | 15,157 | - | - | |
| Herschel S. Weinstein - Officer | Derivative | Stock Option (Right to Buy) | 106,600 | - | - | |
| Herschel S. Weinstein - Officer | Derivative | Stock Option (Right to Buy) | 125,000 | - | - | |
| Herschel S. Weinstein - Officer | Derivative | Stock Option (Right to Buy) | 60,000 | - | - | |
| Herschel S. Weinstein - Officer | Derivative | Stock Option (Right to Buy) | 35,431 | - | - | |
| Francis I. Perier Jr. - Officer | Derivative | Stock Option (Right to Buy) | 368,923 | - | - | |
| Francis I. Perier Jr. - Officer | Derivative | Stock Option (Right to Buy) | 75,000 | - | - | |
| Francis I. Perier Jr. - Officer | Derivative | Stock Option (Right to Buy) | 125,000 | - | - | |
| Francis I. Perier Jr. - Officer | Derivative | Stock Option (Right to Buy) | 60,000 | - | - | |
| Francis I. Perier Jr. - Officer | Derivative | Stock Option (Right to Buy) | 34,419 | - | - | |
| Francis I. Perier Jr. - Officer | Derivative | Common Stock | 60,889 | - | - | |
| Francis I. Perier Jr. - Officer | Derivative | Performance Share Units | 14,724 | - | - | |
| Alan Fuhrman - Director | Derivative | Common Stock | 24,727 | - | - | |
| Alan Fuhrman - Director | Derivative | Stock Option (Right to Buy) | 29,983 | - | - | |
| Alan Fuhrman - Director | Derivative | Stock Option (Right to Buy) | 7,464 | - | - | |
| Alan Fuhrman - Director | Derivative | Stock Option (Right to Buy) | 15,318 | - | - | |
| Alan Fuhrman - Director | Derivative | Stock Option (Right to Buy) | 13,774 | - | - | |
| Alan Fuhrman - Director | Derivative | Stock Option (Right to Buy) | 12,216 | - | - | |
 Daniel Lynch - Director | Derivative | Common Stock | 93,004 | - | - | |
| Daniel Lynch - Director | Derivative | Stock Option (Right to Buy) | 6,447 | - | - | |
| Daniel Lynch - Director | Derivative | Stock Option (Right to Buy) | 232,376 | - | - | |
| Daniel Lynch - Director | Derivative | Stock Option (Right to Buy) | 29,983 | - | - | |
| Daniel Lynch - Director | Derivative | Stock Option (Right to Buy) | 7,464 | - | - | |
| Daniel Lynch - Director | Derivative | Stock Option (Right to Buy) | 15,318 | - | - | |
| Daniel Lynch - Director | Derivative | Stock Option (Right to Buy) | 13,774 | - | - | |
| Daniel Lynch - Director | Derivative | Stock Option (Right to Buy) | 12,216 | - | - | |
| Alan Fuhrman - Director | Grant or award | Common Stock | 10,060 | $0.00 | - | |
| Daniel Lynch - Director | Grant or award | Common Stock | 10,060 | $0.00 | - | |
| Badreddin Edris - Officer | Open-market sale | Common Stock | 11,966 | $41.78 | $500K | |
| Badreddin Edris - Officer | Open-market sale | Common Stock | 8,034 | $42.24 | $339K | |
| Saqib Islam - Officer | Open-market sale | Common Stock | 45,011 | $41.33 | $1.86M | |
| Saqib Islam - Officer | Open-market sale | Common Stock | 3,989 | $41.85 | $167K | |
| Tai-An Lin - Officer | Tax withholding / forfeiture | Common Stock | 2,324 | $32.83 | $76K |
SWTX insider trading FAQ
What is the latest insider trade for SWTX?
SpringWorks Therapeutics, Inc. (SWTX) has filed no insider reports in the last 90 days. The most recent on record is dated 2025-07-01. The full record for SWTX runs to 20 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying SWTX stock?
No insider purchases of SWTX were filed in the last 90 days.
How many insiders are selling SWTX stock?
No insider sales of SWTX were filed in the last 90 days. 4 sales are on record for this company.
Where can I see SWTX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects SWTX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Badreddin Edris view on EDGAR
- - Tai-An Lin view on EDGAR
- - Bhavesh Ashar view on EDGAR
- - James Cassidy view on EDGAR
- - Daniel Pichl view on EDGAR
- - Michael Nofi view on EDGAR
- - Julie Hambleton view on EDGAR
- - Saqib Islam view on EDGAR
- - Carlos Alban view on EDGAR
- - Freda C. Lewis-Hall view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where SWTX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow SWTX with a 7-day demo
- SWTX on your watchlist
- Every SWTX Form 4 filing on record
- Up to 3 months of SWTX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
